M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Phase 2

Recruiting

Conditions: Large B-cell Lymphoma

Interventions: Drug: Prednisone
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Epcoritamab

First Posted Date: 2023-09-21

Last Posted Date: 2025-01-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT06045247

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Spanish Decision Tool for Ovarian Cancer Maintenance Therapy

Not Applicable

Recruiting

Conditions: Ovarian Cancer

Interventions: Other: Shared Medical Decision Tool
Behavioral: Engaging Patients in Decision Making
Behavioral: Literacy Spanish Language

First Posted Date: 2023-09-14

Last Posted Date: 2024-11-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 70

Registration Number: NCT06036810

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine

Phase 1

Recruiting

Conditions: Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions: Drug: Cladribine

First Posted Date: 2023-09-01

Last Posted Date: 2024-12-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT06021600

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy

Not Applicable

Recruiting

Conditions: Brain Metastases

Interventions: Diagnostic Test: 18F-Fluciclovine (Axumin)
Diagnostic Test: Pet Scan

First Posted Date: 2023-08-29

Last Posted Date: 2024-11-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT06015295

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Phase Ib Trial of Eribulin in Combination with Irinotecan and Temozolamide in Children with Relapsed or Refractory Solid Tumors

Phase 1

Recruiting

Conditions: Refractory Solid Tumors

Interventions: Drug: Eribulin
Drug: Irinotecan
Drug: Temozolomide

First Posted Date: 2023-08-23

Last Posted Date: 2024-10-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 48

Registration Number: NCT06006273

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma

Phase 1

Withdrawn

Conditions: Metastatic Hepatocellular Carcinoma

Interventions: Drug: Atezolizumab
Drug: Bevacizumab
Drug: ADI-PEG 20

First Posted Date: 2023-08-23

Last Posted Date: 2024-08-26

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT06006286

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Peripheral Nerve Stimulation of Genicular Nerves Versus Conventional Therapy With Intra-articular Steroid Injection for Chronic Knee Pain: A Prospective, Randomized Pilot Study

Not Applicable

Recruiting

Conditions: Genicular Nerves
Peripheral Nerve Stimulation
Chronic Knee Pain

Interventions: Other: PNS therapy
Drug: Triamcinolone
Other: Placebo
Drug: Bupivacaine

First Posted Date: 2023-08-22

Last Posted Date: 2024-11-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 45

Registration Number: NCT06004882

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)

Phase 2

Recruiting

Conditions: Oligometastatic Renal Cell Carcinoma

Interventions: Drug: Pembrolizumab
Radiation: Radiation therapy

First Posted Date: 2023-08-22

Last Posted Date: 2024-06-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 144

Registration Number: NCT06004336

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Safety, Tolerability, and Efficacy of Enteral Nutrition Versus Paranteral Nutrition in Hematopoietic Stem Cell Transplant Patients: A Pilot Randomized Controlled Study

Not Applicable

Recruiting

Conditions: Stem Cell

Interventions: Dietary Supplement: Enteral nutrition (EN)
Other: Standard care parenteral nutrition (PN)

First Posted Date: 2023-08-22

Last Posted Date: 2024-11-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT06004063

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Prophylactic Lymphovenous Bypass Procedure Following Inguinal Lymphadenectomy: a Prospective Observational Study

Recruiting

Conditions: Lymphadenectomy

Interventions: Procedure: Lymphovenous bypass procedure

First Posted Date: 2023-08-15

Last Posted Date: 2024-12-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT05992909

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy